In order to study the anti-prostate cancer mechanism of gibberellic acid based on network pharmacology and molecular docking method, with a view to providing reference for the elucidation of its clinical anti-prostate cancer mechanism. We used the TCMSP and Swiss TargetPrediction databases to screen the active ingredients and targets of Gynostemma, and used the GeneCards and Disgenet databases to collect the target genes of prostate cancer. Then we used Cytoscape 3.9.1 to construct a drug-active ingredient-target-disease network. For target-disease" network, we used Cytoscape 3.9.1 software, imported potential targets into STRING database to construct protein-protein interaction (PPI) network. And we analyzed the core targets through DAVID database for GO function annotation and KEGG pathway enrichment, and carried out molecular docking between the main active ingredients of Gynostemma gibberelliflorum and the potential targets through Pymol software and AutoDock software. Resultly, the results of GO analysis showed that gibberellic acid's antiprostate cancer may be related to the transcription initiation process of the RNA polymerase II promoter, nuclear chromatin, and DNA binding; the results of KEGG analysis showed that gibberellic acid's antiprostate cancer may involve the cancer pathway, and may be involved in the cancer pathway, and in the cancer. The results of KEGG analysis indicated that gibberellins against prostate cancer might be involved in the cancer pathway, proteoglycan signaling pathway in cancer, microRNA pathway in cancer and thyroid hormone signaling pathway, etc. The results of molecular docking showed that gibberellin LXXIX, the predicted key component of gibberellins, had good binding properties with the core targets of AKT1, IL6 and STAT3. In conclusion, gynostemma gibberelliforme is mainly involved in AKT1, IL6 and STAT3 and 173 signaling pathways, and its active ingredients can inhibit the growth of tumor cells through multi-targets, multi-pathways and multi-mechanisms.

Bai Ge, Tian Bo, Pan Kenian. Mechanism of Gibberellic Acid against Prostate Cancer Based on Network Pharmacology and Molecular Docking. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 11: 97-108. https://doi.org/10.25236/AJMHS.2023.041114.

[1] Si Hongmei, et al. Exploring the potential mechanism of action of Lungwort in the treatment of prostate cancer based on network pharmacology and molecular docking technology [J]. Global Chinese Medicine, 2023, 16(04):668-677. 

[2] Sung Hyuna, Ferlay Jacques, Siegel Rebecca L., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA: A Cancer Journal for Clinicians, 2021, 71(3):209-249. 

[3] Albertsen Peter C. Prostate cancer screening and treatment: where have we come from and where are we going? [J]. BJU international, 2020, 126(2):218-224. 

[4] Alastair Davies, Vincenza Conteduca, Amina Zoubeidi, et al. Biological Evolution of Castration-resistant Prostate Cancer [J]. European Urology Focus, 2019, 5(2):147-154. 

[5] Min Yuen Teo, Dana E. Rathkopf, Philip Kantoff, et al. Treatment of Advanced Prostate Cancer [J]. Annual Review of Medicine, 2019, 70(1):479-499. 

[6] Chang Albert J, Autio Karen A, Roach Mack, et al. High-risk prostate cancer-classification and therapy [J]. Nature reviews. Clinical oncology, 2014, 11(6):308-323. 

[7] Zeng Jianfei. Introduction to the Flora of China [J]. Proceedings of the Chinese Academy of Sciences, 1986(02):176-177. 

[8] Zhong Gansheng, et al. Conceptualization of exploring the training mode of basic skills in traditional Chinese medicine [J]. China Traditional Chinese Medicine Modern Distance Education, 2008(02):108-109. 

[9] Xu Wei. Discussion on the pathogenic factors, metastatic factors and traditional Chinese medicine treatment of prostate cancer based on the theory of "treatment of future diseases" in traditional Chinese medicine [D]. Yangzhou University, 2023.

[10] Zhao San, Huang Haoran, Wang Ruran, et al. Clinical study of Fuzheng and elimination of stasis formula combined with conventional western medicine in the treatment of damp-heat and stasis type of prostate cancer after prostatic hyperplasia surgery [J]. Hebei Traditional Chinese Medicine, 2022, 44(11):1790-1794. 

[11] Li Ziting, Zhang Fengxiang, Fan Cailian, et al. Discovery of potential Q-marker of traditional Chinese medicine based on plant metabolomics and network pharmacology: Periplocae Cortex as an example [J]. Phytomedicine, 2021, 85:153535-153535. 

[12] Duo Jian, Ying Guoguang, Wang Guowen, et al. Quercetin inhibits human breast cancer cell proliferation and induces apoptosis via Bcl-2 and Bax regulation [J]. Molecular medicine reports, 2012, 5(6):1453-1456. 

[13] Bao Xingxun, Li Wei, Jia Ruixue, et al. Molecular mechanism of ferulic acid and its derivatives in tumor progression [J]. Pharmacological reports: PR, 2023, 75(4):891-906. 

[14] Marjorie Reyes-Farias, Catalina Carrasco-Pozo. The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism [J]. International Journal of Molecular Sciences, 2019, 20(13): 3177- 3177. 

[15] Zhao Hongtao, Wang Zhe. Research progress of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer and their therapeutic strategies after drug resistance [J]. Modern Drugs and Clinics, 2021, 36(12):2707-2712. 

[16] Ma Haizhong, Wang Guangdong, Xiang Zhendong, et al. New hotspot in translational medicine research: microRNA regulation of cancer [J]. Journal of Translational Medicine, 2014, 3(05): 265-268+305. 

[17] Wang Haohua, Xiang Guangda. Progress in the study of non-classical nuclear receptor action pathways of thyroid hormones [J]. Medical Review, 2012, 18(18):2961-2964.